Analysis of Circulating Tumor Cells in Patients with Triple Negative Breast Cancer during Preoperative Chemotherapy

被引：5
|
作者：
Lavrov, A. V. [1 ,2 ]
Zubtsova, Zh I. [1 ]
Zubtsov, D. A. [1 ]
Frolova, M. A. [3 ]
Ignatova, E. O. [3 ]
Skrypnikova, M. A. [2 ]
Malysheva, E. V. [3 ]
Legchenko, E. V. [1 ]
Petrovskii, A. V. [3 ]
Utyashev, I. A. [3 ]
Tyulyandin, S. A. [3 ]
Gol'dshtein, D. V. [1 ,2 ]
机构：
[1] State Univ, Moscow Physicotech Inst, Moscow, Russia
[2] Russian Acad Med Sci, Med Genet Res Ctr, Moscow, Russia
[3] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Moscow, Russia
来源：
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE | 2014年 / 157卷 / 01期
基金：
俄罗斯基础研究基金会;
关键词：
circulating tumor cells; breast cancer; STEM-CELL; EXPRESSION; PREDICTS; TRIAL; BLOOD;
D O I：
10.1007/s10517-014-2514-0
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The presence of circulating tumor cells in the blood of patients with triple negative breast cancer (early and locally advanced cancer) before and after preoperative chemotherapy was assessed using expression markers. Before therapy, circulating tumor cells were detected in 5 of 13 (38%) patients with early cancer and in 7 of 17 (41.2%) patients with locally advanced cancer. After therapy, the circulating immune cells were detected in one patient with locally advanced cancer, who had no circulating cells before therapy. The tumor was resistant to chemotherapy and the disease progressed. The detected circulating tumor cells were HER-2-positive, while the primary tumor was HER-2-negative. It was concluded that the circulating immune cells can be a potential marker of the efficiency of therapy and predictors of the disease course, while their phenotype can differ from the phenotype of the primary tumor.
引用
收藏
页码：159 / 161
页数：3
相关论文
共 50 条
  • [11] Caracterization and prognosis in triple negative breast cancer circulating tumor cells
    Abreu Rodriguez, M.
    Cabezas, P.
    Abalo, A.
    Martinez, N.
    Varela, V.
    Garcia, P.
    Sanchez, L.
    Lopez, R.
    Muinelo-Romay, L.
    CLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (03) : 215 - 216
  • [12] Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
    Cavallone, Luca
    Aguilar-Mahecha, Adriana
    Lafleur, Josiane
    Brousse, Susie
    Aldamry, Mohammed
    Roseshter, Talia
    Lan, Cathy
    Alirezaie, Najmeh
    Bareke, Eric
    Majewski, Jacek
    Ferrario, Cristiano
    Hassan, Saima
    Discepola, Federico
    Seguin, Carole
    Mihalcioiu, Catalin
    Marcus, Elizabeth A.
    Robidoux, Andre
    Roy, Josee-Anne
    Pelmus, Manuela
    Basik, Mark
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [13] Monitoring of circulating tumor DNA in metastatic triple-negative breast cancer patients undergoing chemotherapy
    Madic, Jordan
    Kiialainen, Anna
    Bidard, Francois-Clement
    Birzele, Fabian
    Ramey, Guillemette
    Vinolo, Emilie
    Leroy, Quentin
    Rio-Frio, Thomas
    Bernard, Virginia
    Lermine, Alban
    Clausen, Inga
    Giroud, Nicolas
    Schmucki, Roland
    Horn, Carsten
    Spleiss, Olivia
    Lantz, Olivier
    Stern, Marc-Henri
    Pierga, Jean-Yves
    Weisser, Martin
    Lebofsky, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [14] Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy
    Boutrus, Rimoun R.
    Raad, Rita F. Abi
    Kuter, Irene
    Ancukiewicz, Marek
    Roberts, Lisa
    Solomon, Natalie
    Ngo, Taylor
    Borick, Heather
    Ryan, Paula
    Moy, Beverly
    Gadd, Michele
    Chien, Jo
    Younger, Jerry
    Smith, Barbara
    Taghian, Alphonse G.
    Harris, Lyndsay
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2013, 28 (01): : 17 - 23
  • [15] Prognostic Factors for Triple Negative Breast Cancer Patients with Preoperative Systemic Chemotherapy
    Asaga, S.
    Kinoshita, T.
    Hojo, T.
    Suzuki, J.
    Jimbo, K.
    Tsuda, H.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S170 - S171
  • [16] Analysis of circulating tumor cells for monitoring treatment response in triple-negative breast cancer
    Ramirez, Arturo
    Campton, Daniel
    Mahen, Elisabeth
    Blau, C. Anthony
    Kaldjian, Eric Peter
    Stilwell, Jackie L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [17] Dynamics of circulating tumor DNA during postoperative radiotherapy for triple-negative breast cancer in patients undergoing neoadjuvant chemotherapy and breast surgery
    Kim, H.
    Kim, Y. J.
    Park, D.
    Park, W. -Y.
    Choi, D. H.
    Park, W.
    Cho, W. K.
    BREAST, 2021, 56 : S48 - S48
  • [18] Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple negative breast cancer
    Pierga, J-Y.
    Riva, F.
    Houy, A.
    Saliou, A.
    Madic, J.
    Rampanou, A.
    Hego, C.
    Milder, M.
    Cottu, P.
    Sablin, M-P.
    Vincent-Salomon, A.
    Lantz, O.
    Stern, M-H.
    Proudhon, C.
    Bidard, F-C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [19] Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
    Hall, C.
    Hess, R.
    Ravenberg, L.
    Clayborn, A.
    Rauch, G. M.
    Candelaria, R.
    Mittendorf, E. A.
    Moulder, S. L.
    Thompson, A.
    Lucci, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [20] Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I–III Triple-Negative Breast Cancer
    Carolyn Hall
    Mandar Karhade
    Barbara Laubacher
    Amber Anderson
    Henry Kuerer
    Sarah DeSynder
    Anthony Lucci
    Annals of Surgical Oncology, 2015, 22 : 552 - 558
12345